Condition: Ischemic Stroke · Sponsor: Shin Poong Pharmaceutical Co. Ltd.
This clinical study is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (otaplimastat) and thrombolytic standard of care in acute ischemic stroke patient. As a standard of care, thrombolytic therapy (for instance, recombinant tissue plasminogen activator) will be administered. When reperfusion is not achieved in spite of thrombolytic therapy, endovascular therapy can be performed.
This description comes directly from the study's public registry record.
Jong Sung Kim, MD, Phd · +82-33-610-3114 · jongskim@amc.seoul.kr
Byung Su Kim, MS · +82-70-5168-6503 · 135kbs@shinpoong.co.kr
Always discuss trial participation with your own doctor first.
| Dong-A University Hospital | Busan, South Korea | Recruiting |
| Ulsan University Hospital | Ulsan, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06660719